Medicinal chemistry in the new millennium. A glance into the future

被引:41
作者
Erhardt, PW [1 ]
机构
[1] Univ Toledo, Ctr Drug Design & Dev, Coll Pharm, Toledo, OH 43606 USA
关键词
D O I
10.1351/pac200274050703
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The future of medicinal chemistry as both a pure and an applied science has been considered relative to trends that are already having a significant impact upon drug discovery and development. After quickly reviewing how medicinal chemistry has been practiced to date, topics considered into the future include: pursuing therapeutic efficacy, addressing 3D structure within database settings, assuring absorption, directing distribution, controlling metabolism, optimizing elimination, and avoiding toxicity. It is suggested that as the exploration of these topics proceeds into the new millennium by deploying combinatorial chemistry coupled to high-throughput screening, medicinal chemistry will play a key role as a central interpreter of the underlying structure-activity relationships such that the overall process of drug discovery and development will be knowledge-generating. As fundamental knowledge accumulates across all of these areas, virtual approaches will eventually become firmly anchored to experimental and theoretical databases having validated clinical predictability. The potential impact of sonic of the recent trends in process chemistry, and in analytical chemistry using X-ray diffraction as an exemplary method, are additionally highlighted before reiterating the article's major points in a summary section. From this purview, the summary also considers the education of future medicinal chemists, notes potential issues related to the future of pharmaceutical-related intellectual property, and concludes by alluding to a brewing paradox between enhanced knowledge and enhanced molecular diversity relative to the future discovery of new drugs.
引用
收藏
页码:703 / 785
页数:83
相关论文
共 469 条
  • [91] N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists
    Dechantsreiter, MA
    Planker, E
    Mathä, B
    Lohof, E
    Hölzemann, G
    Jonczyk, A
    Goodman, SL
    Kessler, H
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (16) : 3033 - 3040
  • [92] DEGROOT MJ, 1995, DRUG METAB DISPOS, V23, P667
  • [93] A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, p450 102, and P450 108
    deGroot, MJ
    Vermeulen, NPE
    Kramer, JD
    vanAcker, FAA
    denKelder, GMDO
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1996, 9 (07) : 1079 - 1091
  • [94] Devillers J., 1999, Topological Indices and Related Descriptors in QSAR and QSPR
  • [95] Molecular dynamics study of the IIA binding site in human serum albumin:: Influence of the protonation state of Lys195 and Lys199
    Díaz, N
    Suárez, D
    Sordo, TL
    Merz, KM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (02) : 250 - 260
  • [96] DIBIASIO KW, 1989, U MICRO INT, P1
  • [97] DOHERTY AM, 2000, ANNU REP MED CHEM, V35, P331
  • [98] DOLLE RE, 2001, MOD DRUG DISCOV FEB, P43
  • [99] DORFMAN A, 2001, TIME, V157, P97
  • [100] DOWER WJ, 1991, ANNU REP MED CHEM, V26, P271